Loading
Life sciences · Journal article
Expert Review of Clinical Pharmacology · October 30, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
INTRODUCTION: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), established treatments for type 2 diabetes and obesity, are being investigated for substance use disorders (SUDs). Randomized evidence is emerging in alcohol use disorder (AUD), while evidence for opioid, nicotine, cocaine, cannabis, and stimulant use disorders remains mixed, observational, or investigational. AREAS COVERED: This targeted narrative review integrates PubMed/MEDLINE literature, US Food and Drug Administration guidance and labeling, and ClinicalTrials.gov records available through 15 July 2026, with targeted literature and registry updates through 20 October 2026. It evaluates mechanistic plausibility, randomized and real-world human evidence, agent- and dose-specific pharmacology, co-treatment with established SUD medications, safety, adherence, benefit-risk assessment, harm reduction, equity, and trial design. EXPERT OPINION: The evidence is sufficient to justify indication-specific clinical development, especially for AUD, but currently insufficient for routine off-label treatment of SUDs for patients without an approved metabolic indication. Near-term research should test GLP-1 RAs as adjuncts rather than replacements for established SUD care, distinguish direct reward effects from weight loss and adverse-effect pathways, and embed risk minimization, patient-important outcomes, and equitable access into development from the outset.